KR20190075043A - 비시클릭 우레아 키나제 억제제 및 그의 용도 - Google Patents

비시클릭 우레아 키나제 억제제 및 그의 용도 Download PDF

Info

Publication number
KR20190075043A
KR20190075043A KR1020197003642A KR20197003642A KR20190075043A KR 20190075043 A KR20190075043 A KR 20190075043A KR 1020197003642 A KR1020197003642 A KR 1020197003642A KR 20197003642 A KR20197003642 A KR 20197003642A KR 20190075043 A KR20190075043 A KR 20190075043A
Authority
KR
South Korea
Prior art keywords
substituted
unsubstituted
alkyl
certain embodiments
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020197003642A
Other languages
English (en)
Korean (ko)
Inventor
나타나엘 에스. 그레이
얀케 리앙
환 근 최
토마스 선드버그
알리칸 샴지
람니크 사비에르
데이비드 이. 피셔
니스마 무자히드
Original Assignee
더 브로드 인스티튜트, 인코퍼레이티드
더 제너럴 하스피탈 코포레이션
다나-파버 캔서 인스티튜트 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 브로드 인스티튜트, 인코퍼레이티드, 더 제너럴 하스피탈 코포레이션, 다나-파버 캔서 인스티튜트 인크. filed Critical 더 브로드 인스티튜트, 인코퍼레이티드
Publication of KR20190075043A publication Critical patent/KR20190075043A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020197003642A 2016-07-05 2017-07-05 비시클릭 우레아 키나제 억제제 및 그의 용도 Withdrawn KR20190075043A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662358524P 2016-07-05 2016-07-05
US62/358,524 2016-07-05
PCT/US2017/040722 WO2018009544A1 (en) 2016-07-05 2017-07-05 Bicyclic urea kinase inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
KR20190075043A true KR20190075043A (ko) 2019-06-28

Family

ID=59351134

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197003642A Withdrawn KR20190075043A (ko) 2016-07-05 2017-07-05 비시클릭 우레아 키나제 억제제 및 그의 용도

Country Status (10)

Country Link
US (4) US10954242B2 (https=)
EP (2) EP4047001A3 (https=)
JP (1) JP7277357B2 (https=)
KR (1) KR20190075043A (https=)
CN (1) CN110225914A (https=)
AU (1) AU2017291812B2 (https=)
CA (2) CA3293479A1 (https=)
ES (1) ES2920823T3 (https=)
IL (1) IL264106B (https=)
WO (1) WO2018009544A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023063523A1 (ko) * 2021-10-13 2023-04-20 서울대학교산학협력단 류마티스 관절염 예방 또는 치료용 약학적 조성물 및 건강기능식품

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015292818B2 (en) 2014-07-21 2020-01-16 Dana-Farber Cancer Institute, Inc. Imidazolyl kinase inhibitors and uses thereof
AU2017291812B2 (en) 2016-07-05 2023-12-14 Dana-Farber Cancer Institute, Inc. Bicyclic urea kinase inhibitors and uses thereof
WO2018053373A1 (en) 2016-09-16 2018-03-22 The General Hospital Corporation Uses of satl-inducible kinase (sik) inhibitors for treating osteoporosis
BR112019017741A2 (pt) * 2017-02-28 2020-04-07 Dana Farber Cancer Inst Inc usos de pirimidopirimidinonas como inibidores de sik
UA127059C2 (uk) * 2018-03-30 2023-03-29 Ле Лаборатуар Сервьє Гетеробіциклічні інгібітори mat2a і способи використання для лікування злоякісної пухлини
JPWO2020027200A1 (ja) * 2018-08-01 2021-08-19 小野薬品工業株式会社 軟骨関連疾患治療剤
US20230027026A1 (en) * 2019-09-27 2023-01-26 Jubilant Biosys Limited Fused pyrimidine compounds, compositions and medicinal applications thereof
GB201915831D0 (en) 2019-10-31 2019-12-18 Cancer Research Tech Ltd Compounds, compositions and therapeutic uses thereof
GB201915829D0 (en) 2019-10-31 2019-12-18 Cancer Research Tech Ltd Compounds, compositions and therapeutic uses thereof
GB201915828D0 (en) 2019-10-31 2019-12-18 Cancer Research Tech Ltd Compounds, compositions and therapeutic uses thereof
CN115916966A (zh) * 2020-01-30 2023-04-04 加利福尼亚大学董事会 Strad结合剂及其用途
CA3177164A1 (en) * 2020-04-28 2021-11-04 Peter Sennhenn Bicyclic kinase inhibitors and uses thereof
ES3037417T3 (en) * 2020-05-14 2025-10-01 Rhizen Pharmaceuticals Ag Purine derivatives as sik-3 inhibitors
MX2023003087A (es) * 2020-09-16 2023-04-14 Axceso Biopharma Co Ltd Compuesto de pirimido pirimidinona y composicion farmaceutica que comprenden el mismo.
WO2022061312A1 (en) * 2020-09-21 2022-03-24 Soltego, Inc. Sik inhibitors and methods of use thereof
CN116801878A (zh) * 2020-10-05 2023-09-22 达纳-法伯癌症研究所股份有限公司 Her2的有效和选择性抑制剂
CN116529251A (zh) * 2020-12-02 2023-08-01 上海瑛派药业有限公司 取代的稠合双环化合物作为激酶抑制剂及其应用
US20240100177A1 (en) * 2020-12-04 2024-03-28 Dyne Therapeutics, Inc. Antibody-oligonucleotide complexes and uses thereof
WO2022165530A1 (en) * 2021-02-01 2022-08-04 Janssen Biotech, Inc. Small molecule inhibitors of salt inducible kinases
CN116813608B (zh) * 2023-06-08 2024-03-22 英矽智能科技(上海)有限公司 噻唑类化合物及其应用
CN117547615B (zh) * 2023-09-26 2024-12-06 首都医科大学宣武医院 一种纳米囊泡及其制备方法和应用

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4231559B2 (ja) 1997-04-23 2009-03-04 オリザ油化株式会社 リポキシゲナーゼ阻害剤
AU763839B2 (en) 1998-05-26 2003-07-31 Warner-Lambert Company Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation
NZ510760A (en) * 1998-10-23 2003-08-29 F Bicyclic nitrogen heterocycles
US20050202001A1 (en) 2002-04-24 2005-09-15 Han-Mo Koo Enhancement of human epidermal melanogenesis
US7084270B2 (en) 2002-08-14 2006-08-01 Hoffman-La Roche Inc. Pyrimido compounds having antiproliferative activity
US20060094013A1 (en) 2002-08-21 2006-05-04 Hiroshi Takemori Salt-inducible kinases 2 and use thereof
DE10239042A1 (de) 2002-08-21 2004-03-04 Schering Ag Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel
US7112676B2 (en) * 2002-11-04 2006-09-26 Hoffmann-La Roche Inc. Pyrimido compounds having antiproliferative activity
BR0316680A (pt) 2002-11-28 2005-10-18 Schering Ag Pirimidinas inibidoras de chk, pdk e akt, sua produção e uso como agentes farmacêuticos
JP2006522756A (ja) * 2003-04-10 2006-10-05 エフ．ホフマン−ラ　ロシュ　アーゲー ピリミド化合物
US7504396B2 (en) 2003-06-24 2009-03-17 Amgen Inc. Substituted heterocyclic compounds and methods of use
US7442698B2 (en) 2003-07-24 2008-10-28 Amgen Inc. Substituted heterocyclic compounds and methods of use
MXPA06001098A (es) * 2003-07-29 2006-04-24 Irm Llc Compuestos y composiciones utiles como inhibidores de proteina cinasa.
JP4688876B2 (ja) 2004-06-10 2011-05-25 アイアールエム・リミテッド・ライアビリティ・カンパニー タンパク質キナーゼ阻害剤としての化合物および組成物
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
BRPI0514738A (pt) * 2004-08-31 2008-06-24 Hoffmann La Roche derivados de amida de 3-fenil-diidropirimido[4,5-d]pirimidinonas, sua fabricação e aplicação como agentes farmacêuticos
WO2006024545A1 (en) 2004-09-03 2006-03-09 Stichting Voor De Technische Wetenschappen Fused bicyclic natural compounds and their use as inhibitors of parp and parp-mediated inflammatory processes
AU2005322855B2 (en) 2004-12-30 2012-09-20 Exelixis, Inc. Pyrimidine derivatives as kinase modulators and method of use
EP1865959A2 (en) 2005-03-25 2007-12-19 Glaxo Group Limited Process for preparing pyridoý2,3-d¨pyrimidin-7-one and 3,4-dihydropyrimidoý4,5-d¨pyrimidin-2(1h)-one derivatives
RU2007147917A (ru) * 2005-06-10 2009-07-20 Айрм Ллк (Bm) Соединения, поддерживающие плюрипотентность эмбриональных стволовых клеток
BRPI0620408B8 (pt) 2005-12-21 2021-05-25 Novartis Ag derivados de pirimidinil aril uréia sendo inibidores de fgf, seus usos, e preparação farmacêutica
US20090312321A1 (en) 2006-05-15 2009-12-17 Irm Llc Compositions and methods for fgf receptor kinases inhibitors
WO2008060248A1 (en) 2006-11-15 2008-05-22 S*Bio Pte Ltd. Indole sustituted pyrimidines and use thereof in the treatment of cancer
BRPI0819453A2 (pt) 2007-11-28 2014-10-07 Dana Farber Cancer Inst Inc Composto, métodos para tratar um distúrbio relacionado com atividade de cinase, para tratar câncer em um paciente, para inibir a atividade de cinase e para identificar um composto que modula a atividade de cinase de bcr-abl, composição farmacêutica, e, kit
WO2009122180A1 (en) 2008-04-02 2009-10-08 Medical Research Council Pyrimidine derivatives capable of inhibiting one or more kinases
WO2009152027A1 (en) 2008-06-12 2009-12-17 Merck & Co., Inc. 5,7-dihydro-6h-pyrrolo[2,3-d]pyrimidin-6-one derivatives for mark inhibition
AU2009279936A1 (en) 2008-08-05 2010-02-11 Banyu Pharmaceutical Co., Ltd. Therapeutic compounds
CA2745959A1 (en) * 2008-12-12 2010-06-17 Msd K.K. Dihydropyrimidopyrimidine derivatives
AU2010306803A1 (en) 2009-10-14 2012-05-03 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
CN102816162B (zh) * 2011-06-10 2016-04-27 中国科学院广州生物医药与健康研究院 嘧啶并嘧啶酮类化合物及其药用组合物和应用
CA2849999A1 (en) 2011-09-30 2013-04-04 Oncodesign S.A. Macrocyclic flt3 kinase inhibitors
CA2856291C (en) 2011-11-17 2020-08-11 Dana-Farber Cancer Institute, Inc. Inhibitors of c-jun-n-terminal kinase (jnk)
GB201204384D0 (en) 2012-03-13 2012-04-25 Univ Dundee Anti-flammatory agents
JP6378171B2 (ja) 2012-04-24 2018-08-22 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ｄｎａ−ｐｋ阻害剤
GB201212960D0 (en) * 2012-07-20 2012-09-05 Common Services Agency Erythroid production
JP5683634B2 (ja) * 2012-11-28 2015-03-11 株式会社ショーワ 圧力緩衝装置
US9260426B2 (en) 2012-12-14 2016-02-16 Arrien Pharmaceuticals Llc Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors
WO2014138485A1 (en) * 2013-03-08 2014-09-12 Irm Llc Ex vivo production of platelets from hematopoietic stem cells and the product thereof
WO2014140313A1 (en) 2013-03-15 2014-09-18 Oncodesign S.A. Macrocyclic salt-inducible kinase inhibitors
EP3019491A4 (en) 2013-07-09 2016-12-21 Dana Farber Cancer Inst Inc KINASEHEMMER FOR THE TREATMENT OF DISEASES
CN104418860B (zh) * 2013-08-20 2016-09-07 中国科学院广州生物医药与健康研究院 嘧啶并杂环类化合物及其药用组合物和应用
MA38393B1 (fr) * 2014-03-13 2018-11-30 Sanofi Sa Composés hétéroaryle et utilisations associées
US10457691B2 (en) 2014-07-21 2019-10-29 Dana-Farber Cancer Institute, Inc. Macrocyclic kinase inhibitors and uses thereof
AU2015292818B2 (en) 2014-07-21 2020-01-16 Dana-Farber Cancer Institute, Inc. Imidazolyl kinase inhibitors and uses thereof
AU2015300782B2 (en) 2014-08-08 2020-04-16 Dana-Farber Cancer Institute, Inc. Uses of salt-inducible kinase (SIK) inhibitors
KR101850282B1 (ko) 2014-11-26 2018-05-31 한국과학기술연구원 단백질 키나아제 저해제로 유용한 헤테로아릴아민 유도체
CN104482860B (zh) 2014-12-05 2017-10-31 浙江大学宁波理工学院 鱼类形态参数自动测量装置和方法
AU2017291812B2 (en) * 2016-07-05 2023-12-14 Dana-Farber Cancer Institute, Inc. Bicyclic urea kinase inhibitors and uses thereof
WO2018053373A1 (en) * 2016-09-16 2018-03-22 The General Hospital Corporation Uses of satl-inducible kinase (sik) inhibitors for treating osteoporosis
BR112019017741A2 (pt) * 2017-02-28 2020-04-07 Dana Farber Cancer Inst Inc usos de pirimidopirimidinonas como inibidores de sik

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023063523A1 (ko) * 2021-10-13 2023-04-20 서울대학교산학협력단 류마티스 관절염 예방 또는 치료용 약학적 조성물 및 건강기능식품

Also Published As

Publication number Publication date
ES2920823T3 (es) 2022-08-10
JP7277357B2 (ja) 2023-05-18
JP2019527682A (ja) 2019-10-03
US20260078126A1 (en) 2026-03-19
US20210147425A1 (en) 2021-05-20
IL264106B (en) 2022-04-01
US11725011B2 (en) 2023-08-15
EP3481830A1 (en) 2019-05-15
US10954242B2 (en) 2021-03-23
US20200317675A9 (en) 2020-10-08
EP4047001A3 (en) 2022-11-30
CN110225914A (zh) 2019-09-10
US20230234959A1 (en) 2023-07-27
US20190315752A1 (en) 2019-10-17
AU2017291812B2 (en) 2023-12-14
WO2018009544A1 (en) 2018-01-11
CA3069016A1 (en) 2018-01-11
CA3293479A1 (en) 2026-03-02
IL264106A (en) 2019-01-31
AU2017291812A1 (en) 2019-02-21
EP3481830B1 (en) 2022-02-16
EP4047001A2 (en) 2022-08-24
US12398145B2 (en) 2025-08-26

Similar Documents

Publication Publication Date Title
KR20190075043A (ko) 비시클릭 우레아 키나제 억제제 및 그의 용도
JP7200282B2 (ja) サイクリン依存性キナーゼの阻害剤
US12209076B2 (en) Imidazolyl kinase inhibitors and uses thereof
AU2015292827B2 (en) Macrocyclic kinase inhibitors and uses thereof
EP2909204B1 (en) Gsk3 inhibitors and methods of use thereof
KR20160111036A (ko) 디아제판 유도체 및 그의 용도
KR20160115953A (ko) 디아미노피리미딘 벤젠술폰 유도체 및 그의 용도
KR20170032473A (ko) 디아제판 유도체 및 그의 용도
KR20180051576A (ko) 아세트아미드 티에노트리아졸로디아제핀 및 그의 용도
KR20170032474A (ko) 디히드로프테리디논 유도체 및 그의 용도
KR20180049058A (ko) 시아노 티에노트리아졸로디아제핀 및 그의 용도
JP7157075B2 (ja) グリコーゲンシンターゼキナーゼ３（ｇｓｋ３）インヒビターとしての三環式化合物およびそれらの使用
HK40070345A (en) Bicyclic urea kinase inhibitors and uses thereof
HK40013946A (en) Tricyclic compounds as glycogen synthase kinase 3 (gsk3) inhibitors and uses thereof
HK40013946B (en) Tricyclic compounds as glycogen synthase kinase 3 (gsk3) inhibitors and uses thereof
HK40008957B (en) Bicyclic urea kinase inhibitors and uses thereof

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190207

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200703

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220822

Patent event code: PE09021S01D

PC1202 Submission of document of withdrawal before decision of registration

Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment)

Patent event code: PC12021R01D

Patent event date: 20221122

WITB Written withdrawal of application